Report of Foreign Issuer (6-k)
May 23 2019 - 2:00PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
TO RULE 13a-16 or 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the month of May, 2019
Commission File Number: 001-38452
MEREO BIOPHARMA GROUP PLC
(Translation of registrant’s name
into English)
4
th
Floor, One Cavendish
Place,
London, W1G 0QF, United Kingdom
(Address of principal executive office)
Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F
x
Form 40-F
¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
¨
Mereo BioPharma Group plc
("Mereo" or the "Company")
Notification of PDMR and Director Dealing
London, May 23, 2019
- Mereo BioPharma
Group plc (AIM: MPH, NASDAQ: MREO), a clinical stage UK based biopharmaceutical company focused on rare diseases, received notification
that on May 21, 2019, Peter Bains, Director of Mereo, purchased 47,500 ordinary shares at a price of GBP0.90 per share. Peter also
purchased 778 American Depositary Shares (ADSs) at a price of USD4.92 per share.
In addition, on May 22, 2019, John Richard,
Head of Corporate Development at Mereo, purchased 3000 ADSs at a price of USD4.90 per share.
The below announcement and notification
is made in accordance with the EU Market Abuse Regulation. The form required under the EU Market Abuse Regulation follows.
1
|
Details of the person discharging managerial responsibilities
|
a)
|
Name
|
Peter Bains
|
2
|
Reason for the notification
|
a)
|
Position/status
|
Director
|
b)
|
Initial notification/ Amendment
|
Initial notification
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
a)
|
Name
|
Mereo BioPharma Group plc
|
b)
|
LEI
|
213800U8JQHIJOS5AS09
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
a)
|
Description of the financial instrument, type of instrument and identification code
|
MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF £0.003 EACH
|
b)
|
Nature of the transaction
|
PURCHASE
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
GBP0.90
|
47,500
|
d)
|
Aggregated information: volume, Price
|
Aggregated volume: 47,500
Aggregated price: GBP0.90
|
e)
|
Date of the transaction
|
2019-05-21
|
f)
|
Place of the transaction
|
AIMX
|
1
|
Details of the person discharging managerial responsibilities
|
a)
|
Name
|
Peter Bains
|
2
|
Reason for the notification
|
a)
|
Position/status
|
Director
|
b)
|
Initial notification/ Amendment
|
Initial notification
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
a)
|
Name
|
Mereo BioPharma Group plc
|
b)
|
LEI
|
213800U8JQHIJOS5AS09
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
a)
|
Description of the financial instrument, type of instrument and identification code
|
AMERICAN DEPOSITARY SHARE (ADS) EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH
|
b)
|
Nature of the transaction
|
PURCHASE of ADS
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
USD4.92
|
778
|
d)
|
Aggregated information: volume, Price
|
Aggregated volume: 778
Aggregated price: USD4.92
|
e)
|
Date of the transaction
|
2019-05-21
|
f)
|
Place of the transaction
|
XNMS
|
1
|
Details of the person discharging managerial responsibilities
|
a)
|
Name
|
John Richard
|
2
|
Reason for the notification
|
a)
|
Position/status
|
Head of Corporate Development
|
b)
|
Initial notification/ Amendment
|
Initial notification
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
a)
|
Name
|
Mereo BioPharma Group plc
|
b)
|
LEI
|
213800U8JQHIJOS5AS09
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
a)
|
Description of the financial instrument, type of instrument and identification code
|
AMERICAN DEPOSITARY SHARE (ADS) EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH
|
b)
|
Nature of the transaction
|
PURCHASE of ADS
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
USD4.90
|
3000
|
d)
|
Aggregated information: volume, Price
|
Aggregated volume: 3000
Aggregated price: USD4.903
|
e)
|
Date of the transaction
|
2019-05-22
|
f)
|
Place of the transaction
|
XNMS
|
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
Date: May 23, 2019
|
MEREO BIOPHARMA GROUP PLC
|
|
|
|
|
|
|
|
|
By:
|
/s/ Charles Sermon
|
|
|
|
Name:
|
Charles Sermon
|
|
|
|
Title:
|
General Counsel
|
|
Mereo BioPharma (NASDAQ:MREO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Mereo BioPharma (NASDAQ:MREO)
Historical Stock Chart
From Sep 2023 to Sep 2024